Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
作者： E Muraro , E Comaro , R Talamini , E Turchet , G Miolo
DOI: 10.1186/S12967-015-0567-0
关键词: Trastuzumab 、 Neoadjuvant therapy 、 Oncology 、 Cytotoxic T cell 、 Acquired immune system 、 Immunology 、 Immunophenotyping 、 Breast cancer 、 Medicine 、 Immune system 、 Chemotherapy 、 Internal medicine
摘要: Background Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency these together with the immune-modulating activities NC drugs suggest potential contribution host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring locally BC undergoing to identify immunological correlates pCR induction.
biomedcentral.com
uq.edu.au
springer.com
core.ac.uk
elsevier.com参考文章(46)
Xiongwen Wu, Xiufang Weng, Cai'e Zhang, Zhihui Liang, Bing Liang, Lijun Zhu, Xiaoling Lu, Hui Li, A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cellular & Molecular Immunology. ,vol. 3, pp. 453- 458 ,(2006)
Mads Hald Andersen, Sine Reker, Pia Kvistborg, Jürgen C. Becker, Per thor Straten, Spontaneous immunity against Bcl-xL in cancer patients. Journal of Immunology. ,vol. 175, pp. 2709- 2714 ,(2005) , 10.4049/JIMMUNOL.175.4.2709
Eva-Bettina Bröcker, Lars Ø. Pedersen, Jürgen C. Becker, Mads Hald Andersen, Per thor Straten, Barbara Capeller, Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients Cancer Research. ,vol. 61, pp. 5964- 5968 ,(2001)
François Ghiringhelli, Cedric Menard, Pierre Emmanuel Puig, Sylvain Ladoire, Stephan Roux, François Martin, Eric Solary, Axel Le Cesne, Laurence Zitvogel, Bruno Chauffert, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy. ,vol. 56, pp. 641- 648 ,(2007) , 10.1007/S00262-006-0225-8
Naofumi Oda, Kenzo Shimazu, Yasuto Naoi, Koji Morimoto, Atsushi Shimomura, Masashi Shimoda, Naofumi Kagara, Naomi Maruyama, Seung Jin Kim, Shinzaburo Noguchi, Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Research and Treatment. ,vol. 136, pp. 107- 116 ,(2012) , 10.1007/S10549-012-2245-8
C Horlock, B Stott, P J Dyson, M Morishita, R C Coombes, P Savage, J Stebbing, The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. British Journal of Cancer. ,vol. 100, pp. 1061- 1067 ,(2009) , 10.1038/SJ.BJC.6604963
B. Ruffell, A. Au, H. S. Rugo, L. J. Esserman, E. S. Hwang, L. M. Coussens, Leukocyte composition of human breast cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 109, pp. 2796- 2801 ,(2012) , 10.1073/PNAS.1104303108
Cédric Ménard, François Martin, Lionel Apetoh, Florence Bouyer, François Ghiringhelli, Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity Cancer Immunology, Immunotherapy. ,vol. 57, pp. 1579- 1587 ,(2008) , 10.1007/S00262-008-0505-6
Yasmin Issa-Nummer, Sibylle Loibl, Gunter von Minckwitz, Carsten Denkert, Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy. OncoImmunology. ,vol. 3, ,(2014) , 10.4161/ONCI.27926
Timothy Kute, John R. Stehle, Jr., David Ornelles, Natalie Walker, Osvaldo Delbono, James P. Vaughn, Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells OncoImmunology. ,vol. 1, pp. 810- 821 ,(2012) , 10.4161/ONCI.20447